NCT05453188

Physiotherapy for Persistent COVID-19 Disease Using Aerobic Exercise

Completed NA Last updated 14 August 2023

What this trial tests

NA trial testing Experimental in COVID-19 in 30 participants. Completed in 1 July 2022.

Timeline

1 March 2022

Primary endpoint
1 July 2022

1 July 2022

Quick facts

Lead sponsor	Universidad Francisco de Vitoria
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 March 2022
Primary completion	1 July 2022
Estimated completion	1 July 2022
Sites	1 location across Spain

Drugs / interventions tested

• Experimental — full drug profile →
• Control

Conditions studied

• COVID-19 — all drugs for COVID-19 →
• Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →

Sponsor

Universidad Francisco de Vitoria — full company profile →

Who can join

Adults 30 to 60, any sex, with COVID-19 or Genetic Predisposition to Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aerobic exercise - Nordic walking in Persistent Covid (PC) vs. healthy controls.

The main objective of this study is to analyse the genes associated with increased physical performance in patients with PC vs. healthy controls and to measure the level of lactic acid in blood, pre and post exercise session in patients affected by PC.

Relevance: It is intended to be a tool for patients with CP who have not been hospitalised, nor have been offered outpatient rehabilitation treatment. They have not recovered their work, family, sporting or leisure functions. They have particular problems in returning to aerobic exercise.

We think that they may need to be accompanied in the recovery of their physical condition under the supervision of health professionals. Most of the studies offered to them are exploratory, not intervention. Our proposal is a 12-week intervention.

Our proposal, delves into the mechanisms that may underlie their fatigue and their problems in returning to aerobic exercise, in order to collaborate in approaching possible solutions.

Secondary objectives: To study in each of the patients with persistent covid, included in the aerobic Nordic walking programme, their DNA in order to, based on two candidate genes, analyse the role of genetic polymorphisms associated with increased VO2 max training, compared to a healthy control group.

To assess the blood lactic acid level pre and post exercise in a group of patients with persistent covid pre and post aerobic Nordic walking programme. Patients and Methods: 33 patients with CP and 33 healthy controls will follow a Nordic walking programme for 12 weeks. QIAGEN Cube automatic extractor and lactic acid meter will be used.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Effects of Aerobic Exercise Therapy through Nordic Walking Program in Lactate Concentrations, Fatigue and Quality-of-Life in Patients with Long-COVID Syndrome: A Non-Randomized Parallel Controlled Trial.
   Laguarta-Val S, Varillas-Delgado D, Lizcano-Álvarez Á, Molero-Sánchez A, et al · · 2024 · cited 12× · PMID 38398348 · DOI 10.3390/jcm13041035
2. The Association of Genetic Markers Involved in Muscle Performance Responding to Lactate Levels during Physical Exercise Therapy by Nordic Walking in Patients with Long COVID Syndrome: A Nonrandomized Controlled Pilot Study.
   Lizcano-Álvarez Á, Varillas-Delgado D, Cano-de-la-Cuerda R, Jiménez-Antona C, et al · · 2024 · cited 2× · PMID 39125881 · DOI 10.3390/ijms25158305